PREEMPTIVE PHARMACOGENOMIC TESTING FOR PREVENTING ADVERSE DRUG REACTIONS (PREPARE): STATE OF ART AND PRELIMINARY RESULTS ON GENOTYPE ACTIONABILITY

In the last decade several studies have demonstrated that genetic variants in genes involved in drug metabolism and transport affect inter-individual variability in drug efficacy and safety. Since the 1st of January 2016an unique initiative has been launched in Europe with the financial support of Horizon 2020 program, Ubiquitous Pharmacogenomics (U-PGx), under the coordination of Leiden University Medical Center. The core of the project is the PREPARE randomized clinical trial that will be conducted in seven healthcare environments (The Netherlands, Spain, UK, Italy, Austria, Greece, Slovenia).. Primary aim of the study is to evaluate the effect of a pre-emptive pharmacogenomic approach on the prevention of toxic events and the improvement of patients quality of life

Pros-IT CNR: an Italian prostate cancer monitoring project

Aims: The Pros-IT CNR project aims to monitor a sample of Italian males \ue2\u89\ua518\uc2 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. Methods: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, na\uc3\uafve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient\ue2\u80\u99s health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12\uc2 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60\uc2 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. Discussion: The study will provide information on patients\ue2\u80\u99 quality of life and its variations over time in relation to the treatments received for the prostate cancer